IDEAYA Biosciences, Inc.
IDYA · XNASCIK 1676725fmd_18SFRQYGNBFSKT6ER70K4SWE3EManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 20 | 28 | 51 | 23 | 7 | 219 |
| Research and development | 12 | 32 | 34 | 40 | 58 | 90 | 130 | 295 | 315 |
| Total operating expenses | 14 | 36 | 44 | 55 | 78 | 113 | 158 | 334 | 378 |
| Operating income | (14) | (36) | (44) | (35) | (50) | (63) | (134) | (327) | (159) |
| Interest and investment income | 0 | 2 | 2 | – | – | – | – | – | – |
| Other non-operating income (expense) | 2 | 2 | 2 | 1 | 1 | 4 | 21 | 52 | 46 |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (12) | (34) | (42) | (34) | (50) | (59) | (113) | (274) | (114) |